The 4 th Translational Research Symposium (TRS) was organised at the annual meeting of the European Society for Biomaterials (ESB) 2017, Athens, Greece, with a focus on 'Academia-Industry Clusters of Research for Innovation Catalysis'. Collaborations between research institutes and industry can be sustained in several ways such as: European Union (EU) funded consortiums; syndicates of academic institutes, clinicians and industries; funding from national governments; and private collaborations between universities and companies. Invited speakers from industry and research institutions presented examples of these collaborations in the translation of research ideas or concepts into marketable products. The aim of the present article is to summarize the key messages conveyed during these lectures. In particular, emphasis is put on the challenges to appropriately identify and select unmet clinical needs and their translation by ultimately implementing innovative and efficient solutions achieved through joint academic and industrial efforts.
Introduction
The translational research relationships between academic research institutions and industries have been marked by great challenges and hurdles, due to different innovation culture and development goals. Recently, a number of initiatives have emerged to facilitate the transition of innovation processes from academic institutions to industry, consolidating public and/or private partnerships, aiming at accelerating translation of promising new therapies [1] .
Despite the ground-breaking innovations that have been made in many clinical indications, such as oncology, cardiology, haematology, less than 5% of all medical findings made in academia are translated into commercially available solutions [1] . This low rate of translation is disheartening and may be attributed to the hardship to transform ideas or concepts into commercially available products. The initial idea must be aligned with the actual market needs and expectations. Its product development must be well conceived and realistically designed by focusing on translating the idea into a scalable, manufactory robust, cost-effective and user-friendly product. To substantiate this, it is worth noting that a study from 2016 identified that 45% of medical devices that underwent clinical trials obtained regulatory clearance or approval. Most of the devices approved were developed by industry (82%). Devices developed by Andrea de Pieri, Sofia Ribeiro and Dimitrios Tsiapalis share equally first authorship.
* Yves Bayon yves.bayon@medtronic.com collaboration of academia and industry showed greater regulatory approval (13%) than the devices developed by academia alone (5%) [2] . The gap between biomaterials research and clinical applications increases with each passing year. It takes in average 17 years for 14% of original research to be integrated into the clinical practice [3] . The most probable reason for this inefficient outcome derives from today's difficulty to obtain sufficient pre-clinical and clinical proof of concept data, since large companies often resist investment in new innovative solutions, due to the high risk of large capital investments at the early stage of research. Large medical device companies must manage priorities between incremental and disruptive innovations that both have the potential to address an unmet clinical need and enable them to meet commercial goals. Furthermore, the large number of acquisitions in the recent years has led to a documented decline in the rate of innovation on the medical devices field [4] . In order to decrease investor risk aversion, early research in innovative techniques should be conducted in consortia with academia, industry, hospitals and government agencies [5] .
In most cases, the commercial development in the medical devices field goes through two 'valleys of death' (Fig. 1) . The first one is reached when an early stage research starts to be translated into potential clinical solutions. The main hurdle is the lack of financial resources, particularly for very innovative projects. After pre-clinical and clinical validation and completion of the regulatory approval process, there is a possibility of a second valley of death in gaining market acceptance and reimbursement. To overcome these, it is essential to establish at the outset that a new product or treatment properly meets the defined unmet needs and that there is a clear path to both clinical acceptance and to reimbursement. At this point, 42% of start-ups fail, because they do not have a sufficiently identified unmet need and could not find a real market for their product. To successfully commercialise a new product, it is not enough to be safe and effective; the product must satisfy other prerequisites for high adoption rate by clinicians and patients, including: to answer a well-defined and quantifiable unmet clinical need, easy to use (preferably without long and difficult steps of preparation), easy to store (e.g. storage temperature: preferably room temperature; shelf-life: preferably ≥ 1 year) [6] .
There is an increasing need to find creative and effective collaborations for market development and adoption of new solutions, with active involvement of academic institutions, hospitals and companies, starting from the early stages of product development, where a clear definition of what is intended is paramount for its successful conclusion. These concepts and ideas were discussed in detail at the ESB 2017 in Athens, where the 4 th ESB TRS focused on 'Academia-Industry clusters of research for innovation catalysis' with the goal to probe different forms of collaborations between academia and industries. Speakers from industry and research institutes across Europe shared their real-life experience in the clinical translation of biomaterials from both academic and industry point of view. [8] . This project's goal was to develop new and rational design criteria for advanced biomaterials, such as scaffolds for bone, skeletal muscle and cardiac muscles. The project involved comprehensive knowledge in chemistry and physics to successfully translate the outcomes into functional products. The developed scaffolds were evaluated in a multi-parametric in vitro environment that mimicked the natural conditions before reaching the animal model phase. This process was able to reduce the number of animals required and therefore to reduce the cost of bringing new medical devices to the clinic.
The Biodesign project was comprised of a strategic alliance of 21 teams of global experts. The first valley of death was overcome by the scientific partners proving that outcome and technology transfers were feasible. Industry and academia partners collaborated in various projects to deal with the second valley of death. The presence of an industry partner in one example presented was considered a major asset, since it was possible at the outset to construct a clear set of goals and definitions of unmet clinical needs and market expectations. The academic partner in this case brought its in-depth technology knowhow and in addition to scientific papers, this partnership produced 3 patents for an innovative implant interface and new methods of surface coating for delivery of therapeutic agents using biomimetic hydroxyapatite [9] [10] [11] . In the Biodesign project there were many other examples of close-knit and enduring collaborative relationships between both academia and industry producing successful outcomes with numerous published articles in international journals, and the development of state-of-the-art modular scaffolds, such as injectable soft gels, compliant extracellular matrix (ECM) composites and load bearing ceramics [12] [13] [14] and in vitro screening tools to monitor engineered tissues [15] .
Another strategy to bridge the gap between research, clinic and commercial application is the formation of a syndicate of small enterprises with the goal to collaboratively develop a product that has greater commercial and clinical impact than they could achieve as individuals. In this model each partner contributes their unique expertise, resources or services to create a collaborative environment to develop a medical device that is a much larger project than they could manage individually and that is able catch the attention of bigger companies. A practical example of this is the syndicate formed to develop a user-friendlier CaP cement mixing and delivery system. This project was driven by the unmet needs of improving intraoperative mixing and delivery of CaP cements and also to improve screw fixation in poor bone quality bone [16] . It is notable that whilst the screw and cement products currently available for implant fixation are often used in fixation of fragility fractures that these were never qualified in poor quality osteopenic or osteoporotic bone prior to market release.
Even though there was no novelty in the materials used, there were sufficient unmet needs expressed by surgeons that lead to an innovative solution, a hybrid approach, using a biomaterial (iN3 cement) in combination with an implant (N-Force screw). The syndicate successfully overcame both valleys of death obtaining market approvals (CE marking entering the European marketplace and, with an alternative CaP, FDA approval for the US market) and subsequent acquisition of the products by a much larger company Zimmer Biomet.
A medical device developer today has great difficulty to obtain industry investment. On the one hand, if the medical devices/biomaterials are not novel enough, they are often not clinically/commercially attractive and may have intellectual property issues since they have the same 'me too' claims as prior biomaterials. On the other hand, if they are very novel, the risks and investment needed to cover costly preclinical and clinical development phases to prove efficacy discourages investors who seek safe and quick returns on their investments. The recent new Medical Device Regulations (MDR) that have come into force in 2017 will undoubtedly further raise the commercialisation barriers for both 'me-too' and innovative medical devices, as developers are now obliged to assure their product safety and performance by formally documented pre-and/or postmarket clinical data collection [17] .
An alternative syndicate approach was created to develop a novel biomimetic tissue adhesive product. This product aims to meet the unmet need of clinicians to have an adequate strategy for implant fixation in poor bone quality in particular where there are osseochondral bone fragments. A bone adhesive in combination with minimal implant hardware will enable conversion of complex osseochondral fractures, with many small fragments, into a simpler and easier to fix fractures. An adhesive also has great potential to enhance screw fixation in poor bone in both simple and complex multiple fracture treatments. However, there is no existing 'gold' standard against which to benchmark a bone adhesive and no known predicate device, so this development comes with many associated high risks and consequently would not be easily funded by industry. The syndicate innovation here is that the collaborative partners are now running a pre-commercialisation Risk Reduction Project that will engage 5 groups; an industry partner, an academic team (Uppsala University, Sweden), a clinical partner (University of Gothenburg, Sweden), a technology provider (GPBio Ltd, Ireland) and a group of project execution specialists (PBC Biomed Ltd, Ireland). The medical device industry partner has had each of its internal departments identify all the commercially perceived risks. This syndicate now generates data outputs to prove that all defined risks can be mitigated sufficiently to justify moving into a product development cycle to make a bone adhesive product. The risk mitigation pre-commercialisation approach is linked to a commercially attractive 'pay-asyou-go' risk reduction milestones plan. This means that the commercial partner minimises the risk of the first valley of death as the risks of technology transfer from research are visibly and quantifiably mitigated prior to entering formal product development. The bone adhesive project also minimises the risks of the second valley of death since from the outset a clinical partner has worked to define powerful unmet clinical needs where an adhesive is likely to produce clinically measurable better outcomes.
Public incentives for translational research
-The EMPA case
The Swiss Federal Laboratories for Materials Science and Technology (EMPA) is an interdisciplinary research institute of the Swiss Federal Institutes of Technology Domain that plays an important role in the landscape of Swiss and international research. The institution focuses on several research areas, including natural resources and pollutants, energy and sustainable building technologies, nanostructured material and surfaces and health and biomedical technologies. Its mission is to deliver solutions to the society and industries by developing materials and technologies for a sustainable future, whilst its overall aim is to translate research into practice. Due to strong collaborations with various industry partners, EMPA has established efficient technology transfers that allow the transformation of its research outputs into marketable innovations. EMPA acts as a bridge between academia and companies, serving as a platform for knowledge transfer from basic research to the practical implementation of new ideas. Among others, EMPA is supported by Innosuisse (formerly known as Commission for Technology and Innovation, CTI) to carry out joint research between academic institutes and companies. Innosuisse supports innovation projects which cannot be implemented by industry due to lack of expertise and financial resources. It is also active in several other funding areas such as support of start-ups, funding of public research institutions in connection with innovation projects together with SMEs and encouraging the knowledge and technology transfer between universities and companies. It plays a crucial role in the ecosystem of innovation, creating a strong collaborative network between companies and public research. This enables companies to benefit from the expertise of specialist researchers and from the facilities available in the educational institutions. In return, researchers have access to entrepreneurial know-how and to national and international markets. Innosuisse promotes science-based innovation in a unique way, by encouraging the collaborations and the transmission of the know-how between the partners, rather than by making direct payments to the SMEs. Innosuisse payments are always aimed directly at the research partner of an innovation project. The SMEs must participate with at least 50% of the project costs themselves. In 2016, Innosuisse supported 539 innovation projects with a total amount of CHF 186.5 m. EMPA collaborated in 31 innovation projects, which received Innosuisse funding of CHF 11.9 million.
Moreover, Innosuisse in a 50:50 shared effort together with the Swiss National Science Foundation (SNF) supplements funding activities with a programme called BRIDGE, which aims to foster the translation of scientific results into marketable products or technologies, closing the gap between basic research and market. The programme consists of two funding schemes ('proof-of-concept' and 'discovery') and has a budget of CHF 70 million for the period of 2017-2020. In 2017, 32 proof-of-concept and 8 discovery project applications were approved.
A representative example is the collaboration between the Biointerface lab at EMPA and two industrial partners to develop an antibacterial surface coating for orthopaedic implants. Orthopaedic surgical site infections (SSI) are a clinical burden for healthcare system representing 20% of the health-care associated infections [18, 19] . The risk factors associated with SSI are mainly due to patient-related characteristics or to procedure-related factors, especially the site and the nature of the implant [20] . These complications lead to an increase of financial costs, due to additional treatments and longer periods of hospitalization. It is estimated that orthopaedic SSIs prolong total hospital stays by a median of two weeks per patient, approximately double readmission rates and increase healthcare costs by more than 300%. Moreover, patients with orthopaedic SSIs have substantially greater physical limitations and significant reductions in their quality of life. Infectious complications may range from superficial infections to deep and organspace infections, many of which may be associated with increased mortality. For these reasons, it is becoming imperative to develop new strategies to prevent bacterial infections. Normally, prophylactic systemic antibiotics are administered to the patients who undergo surgeries to prevent post-implantation infections. However, these treatments have several drawbacks mainly due to the relative low drug concentration at the target site and increased resistance of bacteria [21] . Therefore, an implant surface with antibacterial properties, either by preventing bacteria adhesion or by being bactericidal, could prevent infectionrelated problems following implantation surgeries [22] [23] [24] . Considering the risk of antibiotic resistance, non-antibiotic agents in the coatings become very attractive alternatives. Therefore, the aim of the project is to develop a nonantibiotic based solution that combines biocompatibility and tribological properties of implant surfaces.
The challenge of the project consists in its multidisciplinary, ranging from the optimization of the coating processes, the in vitro testing of the products, the potential in vivo applications, to the commercialization of the final products. Preliminary results are encouraging to conduct further studies and potential market applications of the final product. This collaboration is an outstanding example for a synergism of excellent research skills from an educational institute and high technological skills from the industry with the final aim to translate basic research into a final product to the market. 4 The missing piece of the puzzle-The example of Ghent University-Allnex collaboration
There are various reasons for initiating co-operations between academic institutes and industry in biomedical science, including the sharing of complementary knowledge to solve specific technical problems, such as prototyping, manufacturing and characterization. Usually, most of partnerships are built up with entities working in similar research areas or with previous research experience in common projects. However, they can be also successful, and probably more creative, between partners which appear be divergent at a first sight. One example of such a partnership was presented at the ESB TRS in Athens. The Polymer Chemistry & Biomaterials group from University of Ghent (PBM-UGent) works closely with the company Allnex, for the development of polymer-precursors of hydrogels, suitable for 3D printing, electro-spinning and 2-photon polymerization applications. Interestingly, the company Allnex, which is a leading supplier of specialty chemicals, was not primarily developing chemicals for biomedical applications. Mainly, it produces non-biocompatible polymers, catalysts, additives and cross-linkers for use on wood, metal, plastic and other surfaces. Thinking out of the box, PBMUGent addressed to Allnex for the development of biocompatible polymers with various biomedical applications. 3D printing, electro-spinning and 2-photon polymerization technologies have stimulated a great interest for potential applications in regenerative medicine and tissue engineering due to their ability to produce implantable scaffolds of any 3D shape for soft and hard tissue repair [25] [26] [27] [28] [29] . Prior to scaffold application, certain polymers need to be cross-linked to improve their intrinsic properties and become appropriate for tissue engineering applications. Ultraviolet (UV) irradiation has been extensively used as a cross-linking technique to prepare scaffolds from natural and synthetic polymers [30] . Importantly, available scaffold precursors can only be UV-cross-linked in solution or in the molten state, an approach that is highly demanding [31] . The aim of PBM-UGent group and Allnex was to develop different types of cross-linkable polymers, bypassing the current limitations. Researchers in PBM-UGent group together with Allnex, designed urethane-based polymers (backbone), connected to a mono-acrylated spacer in both sides using a di-isocyanate linker. The backbone molecule (e.g. polyethylene glycol and poly-ε-caprolactone) determines the characteristics of the polymer, such as the hydrophilicity or hydrophobicity, the mechanical properties and the degradation, while the mono-acrylated spacer influences the photo-reactivity of the precursor, as well as impacts the degradation rates of the polymer [32] . These novel precursors exhibit unique properties of being crosslinked in the solid state without the addition of any solvent, allowing then to pre-shape the material by 3D printing or electro-spinning, to meet the in vivo degradation profile specifications. In addition, the modified polymers showed adjustable melting points, and degradation kinetics and very large water solubility. Moreover, the produced 3D-scaffolds showed increased cytocompatibility as the cross-linking of the materials can occur in the absence of photo-initiators, which induce toxicity contrary to most other photoactivation approaches.
The technology presented by PBM-UGent group and Allnex provides different material compositions with different cross-linked networks depending on the application. Also, flexible compositions can be designed depending on the hydrophilicity and hydrophobicity properties of the material, the different mechanical properties, the porosity and the cross-linking rate. The designed materials can be then processed through 3D printing or electro-spinning and can be used for various biomedical applications as tissue engineering materials, contact lenses, wound bandages, delivery systems for bioactive molecules and as coatings for implants.
Besides designing a novel range of products for biomedical applications, a partnership between universities and companies can be characterized successful, if this product can be scaled up and can be commercially available. The designed scaffold precursors are still under investigation for potent biomedical applications, but the technology has been already patented and both partners are willing to translate their promising methodology to commercial products. Furthermore, the facilities of Allnex in collaboration with other industrial partners and its expertise in commercialisation can ensure the vast production as well as the delivery of the developed polymers into the market.
Conclusion
The translation of novel research ideas or concepts into advanced therapies adopted in the clinics faces many challenges, including the lack of expertise in implementing viable strategies for clinical applications, the lack of expertise in cost-effective industrialization and in commercialization. A close collaboration between different partners with specific and complementary know-how should overcome these barriers.
The clinical translation can be very expensive and risky considering its high failure rate. It is crucial to clearly identify the unmet needs before starting a new product development project. It is just as important to invest time and money, from the very first steps, to get user friendly products (e.g. easiness of use; friendly storage conditions). Paying a great attention at the unmet clinical needs and the product usability as early as possible improves the chances of success. However young entrepreneurs should have an open mind and flexible opportunistic spirit to make an idea, into a product, into a possible success, into an impactful therapy. In this paper were given some examples of different academia and industry partnership schemes, which effectively answered needs of product development. All presented cases, particularly the development of a novel biomimetic tissue adhesive product, are leading to the same conclusion. If we are willing to let go of our preconceived ideas, we should be in a better position to put the puzzle of product development together. In other words, it is imperative to find the right missing partners to bring the original idea or concept into the clinics. In order to face the rapid technological change and address the still or emerging unmet clinical needs in the medical devices sector, governments start fostering the collaborations between universities, clinics and industries to improve the clinical translation of new ideas and their adoption in the clinics [e.g. Science Foundation Ireland (SFI) Centre for Research in Medical Devices (CÚRAM)]. At EU level, several programmes have encouraged the collaboration between industry and academia. FP programmes have attempted to create a network of regional R&D collaborations [33] . The impact of FP participation differs extensively depending on the nature, size and field of the company. A European study concluded that most small and medium enterprises (SMEs) benefited to a greater extent from FP participation than larger companies. While SMEs give higher importance to funding, large companies prioritise networking [34] . Moreover, Fast Track to Innovation (FTI), Small and Medium-sized Enterprises (SME) instrument, Future and Emerging Technologies (FET) Open and Horizon Prizes, launched under the umbrella of the last Framework Programme Horizon 2020, have promoted close to the market technologies and applications.
Both public and private sectors have made efforts to support and fund research for effective early product development projects. However, both sectors lack the resources to support regulatory science research. It is expected that improvements and advances in regulatory science would speed up the translation of next-generation technologies [35] . To spur innovation in regulatory science in the medical technology field, a non-profit organization was formed in late 2012 in the US. The Medical Device Innovation Consortium (MDIC) has the goal to improve human health and brings together federal entities like the U. S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Centers for Medicare and Medicaid Services (CMS), the industry and the non-profits and patent organizations. Platforms, such as MDIC, should be created in other countries, as they will form a foundation for a collaborative freeway between industry, academia, clinics and government, facilitating the advance of knowledge that modernizes regulatory science that will ultimately improve patient access to high-quality medical devices.
